Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of
several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of
treatment in patients with Type 2 diabetes and insufficient glycemic control. In addition,
there will be an open-label treatment arm with metformin for sensitivity measurement with
this patient population. Population pharmacokinetics of BI 1356 BS will also be assessed in
this study.